Company / Free Cash Flow
Monte Rosa Therapeutics, Inc. Free Cash Flow History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$38.0M
FY2024
5-year range
-$105.4M / $38.0M
FY2020-FY2024
Trend
+160.5%
vs FY2023
Sector context
#59 of 194
Health Care
What the data says
At $38M, Monte Rosa Therapeutics, Inc.'s free cash flow ranks #59 of 194 in the Health Care sector. Improved from -$105M to $38M over the past 2 years.
Based on SEC 10-K filings.
$38M in FY2024.
Improved from -$105M to $38M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#59 of 194 in Health CareTop 30% of 194This company $38.0M Sector average $470.6M
▼
-91.9% below sector average
Key checks
Key Insights
- In FY2024, free cash flow increased 160.5% year-over-year.
- Ranks #59 out of 194 companies in the Health Care sector.
- Lowest free cash flow in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score 0.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $38.0M | +160.5% |
| FY2023 | -$62.8M | +40.4% |
| FY2022 | -$105.4M | -52.5% |
| FY2021 | -$69.1M | -161.3% |
| FY2020 | -$26.4M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026